

Cuban Biotechnology develops 15 projects to face the pandemic

By: Radio Cadena Agramonte
12/04/2020



Cuban scientists are working on 15 biotechnological projects to confront Covid-19 that encompass diagnosis and treatment, officials from BioCubaFarma announced .

Orlando Pérez Rodríguez, director of Science and Innovation of BioCubaFarma, said this Friday that all clinical research and interventions have been duly authorized by Cuban regulatory entities and will be timely evaluated and reported to publicize the experience. He explained that six of the 15 projects are focused on treatment, the same number are prophylactic, and two are for diagnosis.

He added that the products focus on increasing people's immunity, reducing the viral load at the beginning of the disease and reducing the hyperinflammatory reaction in patients who develop it, especially in older adults or those with background pathologies.

Nine of these projects are already in the phase of intervention trials or

clinical studies and six are still in the research and development phase in laboratories, in addition to others in the design or early research.

Most products focus on the use of prophylactics, including the nasal administration of interferon Alfa (to stimulate immunity), biomodulin-T (for those over 60 years of age), transfer factor (stimulates immunity in vulnerable groups), CIGB 2020 (immuno enhancer) and a vaccine candidate from the Finlay Institute (contains components of the Cuban meningitis vaccine).

The specialist added that among the projects that are in the research phase two anti-viral peptides appear, a vaccine to induce specific protective immunity in case of a re-emergence of the disease, as well as the design of lung ventilators by the CNEURO and COMBIOMED, ??some of whose pieces would be obtained through 3D printing.
